CKLIFE SCIENCES0775.HKValuation Analysis

As of Oct 16, 2026, CKLIFE SCIENCES (0775.HK) trades at a negative P/E (-75.76x, due to a recent net loss), P/B of 1.25x, P/S of 0.89x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 27th percentile over the trailing 10Y window (vs. 32nd percentile over 3Y); P/S sits at the 20th percentile over the trailing 10Y window (vs. 32nd percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 59th percentile within its industry and the 61st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. CKLIFE SCIENCES operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.